261 related articles for article (PubMed ID: 33574757)
1. Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Su D; Wu B; Shi L
Front Pharmacol; 2020; 11():610601. PubMed ID: 33574757
[No Abstract] [Full Text] [Related]
2. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
Teppala S; Scuffham PA; Tuffaha H
Int J Technol Assess Health Care; 2024 Mar; 40(1):e14. PubMed ID: 38439629
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Wu B; Shi L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1528-1536. PubMed ID: 33152708
[TBL] [Abstract][Full Text] [Related]
4. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.
Xu C; Cai J; Zhuang J; Zheng B; Chen L; Sun H; Zheng G; Wei X; Liu M
Ann Transl Med; 2022 Aug; 10(15):830. PubMed ID: 36034977
[TBL] [Abstract][Full Text] [Related]
6. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
7. Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective.
Matsumoto T; Shiota M; Blas L; Eto M
Cancer Manag Res; 2022; 14():2389-2397. PubMed ID: 35967752
[TBL] [Abstract][Full Text] [Related]
8. Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in
Li Y; Lin S; Zhong L; Luo S; Huang X; Huang X; Dong L; Xu X; Weng X
Pharmacogenomics; 2021 Aug; 22(13):809-819. PubMed ID: 34517749
[No Abstract] [Full Text] [Related]
9. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.
LeVee A; Lin CY; Posadas E; Figlin R; Bhowmick NA; Di Vizio D; Ellis L; Rosser CJ; Freeman MR; Theodorescu D; Freedland SJ; Gong J
Onco Targets Ther; 2021; 14():4819-4832. PubMed ID: 34552338
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
Stopsack KH
Eur Urol; 2021 Apr; 79(4):442-445. PubMed ID: 33012578
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
12. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report.
Yuan F; Liu N; Yang MZ; Zhang XT; Luo H; Zhou H
World J Clin Cases; 2022 Apr; 10(11):3461-3471. PubMed ID: 35611209
[TBL] [Abstract][Full Text] [Related]
15. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
16. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
18. Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Warli SM; Velaro AJ; Firsty NN; Tala ZZ
World J Oncol; 2023 Dec; 14(6):518-528. PubMed ID: 38022404
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
[TBL] [Abstract][Full Text] [Related]
20. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.
Chau V; Madan RA; Figg WD
Cancer Biol Ther; 2020 Oct; 21(10):884-887. PubMed ID: 32844710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]